TRAITEMENT DU CANCER DU SEIN TRIPLE NÉGATIF OU DU CANCER COLORECTAL COMPORTANT DES MÉTASTASES HÉPATIQUES PAR UN ANTICORPS ANTI-PD-L1 ET UN VIRUS ONCOLYTIQUE

TRAITEMENT DU CANCER DU SEIN TRIPLE NÉGATIF OU DU CANCER COLORECTAL COMPORTANT DES MÉTASTASES HÉPATIQUES PAR UN ANTICORPS ANTI-PD-L1 ET UN VIRUS ONCOLYTIQUE

Provided herein are methods of treating a subject with triple negative breast cancer or colorectal cancer. In exemplary embodiments, the method comprises administering to the subject a combination of an oncolytic virus, such as talimogene laherparepvec, and an anti-PD-L1 antibody, such as atezolizum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHA, Edward Namserk, BHATTA, Sumita, Shankar, WOODARD, Joseph, Paul, GANSERT, Jennifer, Lorraine
Format: Patent
Sprache:fre
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Provided herein are methods of treating a subject with triple negative breast cancer or colorectal cancer. In exemplary embodiments, the method comprises administering to the subject a combination of an oncolytic virus, such as talimogene laherparepvec, and an anti-PD-L1 antibody, such as atezolizumab. In exemplary aspects, the oncolytic virus is administered to the subject at an initial dose followed by a second dose, wherein the initial dose is lower than the second dose. In exemplary aspects, the oncolytic virus is intrahepatically administered to the subject.